

NEWSLETTER

Dear friends and colleagues,

INCEPT has been active for a year now. Together we have reached major milestones, for which we should be very proud and congratulate each other:

>1200 randomisations in >1000 unique participants.

15 Danish ICUs are active.

2 domains are active, another 2 are funded and on the way.

The monitoring reports look good with few issues!

The quality of the data when cleaned for the feasibility analyses look good!

The annual safety report has been approved, and we continue unchanged.

INCEPT is approved in the Netherlands, Sweden, Finland and Iceland. These countries will be initiated after the summer break.

The documents for approvals have been submitted for Norway, Estonia, Austria and Saudi Arabia.



Important notes

As mentioned, the annual safety report has been approved. It has been uploaded on www.incept.dk and should be printed/saved for the site file.

Importantly, we continue INCEPT unchanged.

Updates

Stakeholder involvement

The protocol for the core outcome measurement set (CoreMS-ICU) has been accepted for publication. Stakeholders contributed to defining the six core outcomes and will be involved again in consensus meetings to select the outcome measurement instruments (planned in about a year).

In the meantime, we are mapping instruments and assessing their quality.

A research panel from Aalborg developed a folder and poster for family members about intensive care research in general, for use in waiting rooms.

The national steering committee has since revised both to make them applicable across Denmark. If there is interest, we can translate them for use in other countries.

On June 19, we will hold a research panel meeting with the INCEPT-Bicarbonate sponsor (Asger Granfeldt) in Copenhagen to review the information materials and discuss the intervention and outcomes.

At this meeting, we will also discuss the INCEPT website for patients and family members.

Data

In the future we would like to send notices about queries, technical problems etc., out through the EasyRF system. The information will typically be sent out to all those that are registered with a “trial registrar role”.



Some sites have quite a few assigned to this role. If you, as an individual, find it inappropriate to receive these emails, then reach out to your site investigator at your site whether you should have another role in the EasyRF or not.

Funding

Several funding applications have been submitting and await assessments – this is an ongoing process.

Clinical domains

As you know we have translated all the information material to patients and relatives into several languages – to be used in a Danish setting.

Now, we have translated the information into Greenlandic as well, but we need to validate the information by having a native speaking health care professional with insight into the area. Unfortunately, we do not have a regular budget to pay for it, but a humble acknowledgement will be possible.

If anyone in this network know someone who can help us doing it, please contact Rikke by sending an email to contact@incept.dk

Albumin domain

Data analyses for the feasibility phase are ongoing.

Thromboprophylaxis domain

Data analyses for the feasibility phase are ongoing.

Upcoming events

➤ The next INCEPT/EasyRF workshop will be held August 21, 2026.
Click [here](#) to register for participation.



➤ PhD course “Patient and public involvement in health research”, August 25-26, 2026.
Click [here](#) to register.

➤ The next INCEPT Management committee meeting will be held August 26, 2026

➤ The next INCEPT Network meeting will be held September 30, 2026

Enrolment overview

June 2025 to June 2026



If you have any ideas, suggestions, or updates to coming or previously discussed domains not listed above (i.e., domains that are early in the planning phase), that you would like to discuss at future meetings, please reach out to Morten (morten.hylander.moeller@regionh.dk).

With collegial regards,

The INCEPT Coordinating Group

Anders Granholm, Anders Perner, Morten Hylander Møller,
Maj-Brit Nørregaard Kjær, and Rikke Faebo Larsen

